High dose salvage therapy with dose intensive cyclophosphamide, etoposide and cisplatin may increase transplant rates for relapsed/refractory aggressive non-Hodgkin lymphoma

References

• Philip T, Guglielmi C, Hagenbeek A, et al. Autologous bone marrow transplantation as compared with salvage chemotherapy in relapses of chemotherapy-sensitive non-Hodgkin's lymphoma. N Engl J Med 1995;1540–1545.
   PubMed Web of Science ®Google Scholar
• Oliansky DM, Czuczman M, Fisher RI, et al. The role of cytotoxic therapy with hematopoietic stem cell transplantation in the treatment of diffuse large B cell lymphoma: update of the 2001 evidence-based review. Biol Blood Marrow Transplant 2011;17:20–47.e30
   PubMed Web of Science ®Google Scholar
• Vose JM, Rizzo DJ, Tao-Wu J, et al. Autologous transplantation for diffuse aggressive non-Hodgkin lymphoma in first relapse or second remission. Biol Blood Marrow Transplant 2004;10:116–127.
   PubMed Web of Science ®Google Scholar
• Kewalramani T, Zelenetz AD, Nimer SD, et al. Rituximab and ICE as second-line therapy before autologous stem cell transplantation for relapsed or primary refractory diffuse large B-cell lymphoma. Blood 2004;103:3684–3688.
   PubMed Web of Science ®Google Scholar
• Gisselbrecht C, Glass B, Mounier N, et al. Salvage regimens with autologous transplantation for relapsed large B-cell lymphoma in the rituximab era. J Clin Oncol 2010;28:4184–4190.
   PubMed Web of Science ®Google Scholar
• Crump M, Kuruvilla J, Couban S, et al. Gemcitabine, dexamethasone, cisplatin (GDP) compared to dexamethasone, cytarabine, cisplatin (DHAP) chemotherapy prior to autologous stem cell transplantation for relapsed and refractory aggressive lymphomas: final results of the randomized phase III NCIC CTG study LY12. Blood 2012; 120(Suppl. 1):Abstract 745.
   Google Scholar
• Cheson BD, Pfistner B, Juweid ME, et al. Revised response criteria for malignant lymphoma. J Clin Oncol 2007;25:579–586.
   PubMed Web of Science ®Google Scholar
• Freyer C, George T, Price S, et al. R-ICE versus R-ESHAP for salvage therapy in aggressive B-cell non-Hodgkin lymphoma. J Clin Oncol 2012;30(Suppl.):Abstract e18509.
   Google Scholar
• Vellenga E, van Putten WLJ, van't Veer MB, et al. Rituximab improves the treatment results of DHAP-VIM-DHAP and ASCT in relapsed/progressive aggressive CD20 + NHL: a prospective randomized HOVON trial. Blood 2008;111:537–543.
   PubMed Web of Science ®Google Scholar
• Lokich J, Anderson N. Dose intensity for bolus versus infusion chemotherapy administration: review of the literature for 27 anti-neoplastic agents. Ann Oncol 1997;8:15–25.
   PubMed Web of Science ®Google Scholar
• Damon L, Damon LE, Gaensler K, et al. Impact of intensive PBSC mobilization therapy on outcomes following auto-SCT for non-Hodgkin's lymphoma. Bone Marrow Transplant 2008;42: 649–657.
   PubMed Web of Science ®Google Scholar
• Cortelazzo S, Rambaldi A, Rossi A, et al. Intensification of salvage treatment with high-dose sequential chemotherapy improves the outcome of patients with refractory or relapsed aggressive non-Hodgkin's lymphoma. Br J Haematol 2001;114:333–341.
   PubMed Web of Science ®Google Scholar
• Stewart D, Guo D, Morris D, et al. Superior autologous blood stem cell mobilization from dose-intensive cyclophosphamide, etoposide, cisplatin plus G-CSF than from less intensive chemotherapy regimens. Bone Marrow Transplant 1999;23:111–117.
   PubMed Web of Science ®Google Scholar
• Moore S, Peggs K, Thomson K, et al. Autologous stem cell transplantation remains beneficial for patients relapsing after R-CHOP chemotherapy and who respond to salvage chemotherapy. Br J Haematol 2012;156:142–143.
   PubMed Web of Science ®Google Scholar
• Smith SD, Bolwell BJ, Rybicki LA, et al. Comparison of outcomes after auto-SCT for patients with relapsed diffuse large B-cell lymphoma according to previous therapy with rituximab. Bone Marrow Transplant 2011;46:262–266.
   PubMed Web of Science ®Google Scholar
• Tarella C, Zanni M, Magni M, et al. Rituximab improves the efficacy of high-dose chemotherapy with autograft for high-risk follicular and diffuse large B-cell lymphoma: a multicenter Gruppo Italiano Terapie Innnovative nei Linfomi Survey. J Clin Oncol 2008;26:3166–3175.
   PubMed Web of Science ®Google Scholar
• Metayer C, Curtis RE, Vose J, et al. Myelodysplastic syndrome and acute myeloid leukemia after autotransplantation for lymphoma: a multicenter case-control study. Blood 2003;101:2015–2023.
   PubMed Web of Science ®Google Scholar
• Hosing C, Munsell M, Yazji S, et al. Risk of therapy-related myelodysplastic syndrome/acute leukemia following high-dose therapy and autologous bone marrow transplantation for non-Hodgkin's lymphoma. Ann Oncol 2002;13:450–459.
   PubMed Web of Science ®Google Scholar
• Hill BT, Rybicki L, Bolwell BJ, et al. The non-relapse mortality rate for patients with diffuse large B-cell lymphoma is greater than relapse mortality 8 years after autologous stem cell transplantation and is significantly higher than mortality rates of population controls. Br J Haematol 2011;152:561–569.
   PubMed Web of Science ®Google Scholar
• Cuccuini W, Briere J, Mounier N, et al. MYC+ diffuse large B-cell lymphoma is not salvaged by classical R-ICE or R-DHAP followed by BEAM plus autologous stem cell transplantation. Blood 2012;119:4619–4624.
   PubMed Web of Science ®Google Scholar
• Thieblemont C, Briere J, Mounier N, et al. The germinal center/activated B-cell subclassification has a prognostic impact for response to salvage therapy in relapsed/refractory diffuse large B-cell lymphoma: a bio-CORAL study. J Clin Oncol 2011;29:4079–4087.
   PubMed Web of Science ®Google Scholar